Regorafenib in Advanced and Refractory Gastrointestinal Cancers

*Ewen D. Legg

Halcyon Medical Writing LTD., Thurso, UK
*Correspondence to ewen.d.legg@gmail.com

Disclosure: Medical writing assistance was funded by Bayer.
Received: 08.02.16 Accepted: 09.03.16
Citation: EMJ. 2016;1[2]:18-25.

Abstract

The American Society of Clinical Oncology’s 2016 Gastrointestinal Cancer Symposium (ASCO-GI), held in San Francisco, California, USA, provided a forum for leading basic scientists and clinical cancer specialists to discuss cutting-edge research in the field of gastrointestinal (GI) oncology. The quest to improve outcomes and patient lives by targeting unmet clinical need, such as refractory illness, fuelled much of the research presented at the 2016 edition of ASCO-GI. The symposium saw the presentation of a number of studies on the current stage of clinical research on regorafenib, an oral tyrosine-kinase inhibitor approved for use in both refractory metastatic colorectal cancer and metastatic GI stromal tumours.

Download (PDF, 123KB)

Comments are closed.